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The importance of glycosylation i cell surface xpression of muscarinic receptors in cultured guinea pig pancreatic acini was investigated. Recovery 
of the muscarinic receptor population after carbachol-induced down regulation was blocked by cycloheximide but not by tunicamycin, although 
tunicamycin reduced [aH]mannose incorporation i to acinar macromolecules byup to 90%. Tunicamycin treatment also failed to alter carbachol 
stimulation of amylase secretion from cultured acini. These results indicate that glycosylation of the glandular subtype of muscarinic receptor in 
the pancreatic acinar cell is not necessary for its insertion in the plasma membrane or for its functional activity. 
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1. INTRODUCTION 
Cholinergic agonists are potent stimulators of 
digestive nzyme secretion in the exocrine pancreas, an 
effect mediated by muscarinic acetylcholine r ceptors 
[1,2]. Recent pharmacological and molecular biological 
studies have indicated that glandular muscarinic recep- 
tors constitute a separate subtype (M3) that is distinct 
from both the cardiac M2 subtype and the M1 subtype 
that predominates in the central nervous ystem [3-5]. 
Both neuronal and myocardial muscarinic receptors 
have been shown to be glycoproteins [6,7], and se- 
quence information predicts the presence of at least 4 
sites for N-linked glycosylation i  the M3 receptor sub- 
type [5]. Liles and Nathanson [8] have shown that 
glycosylation of muscarinic receptors in mouse NE-115 
neuroblastoma cells is important for maintenance of
the plasma membrane receptor population. Com- 
parable studies have not been carried out on exocrine 
gland cells. We therefore have examined the effects of 
tunicamycin, an inhibitor of N-glycosylation, aswell as 
cycloheximide, on the recovery of muscarinic receptors 
that follows down regulation elicited by the cholinergic 
agonist carbachol in cultured guinea pig pancreatic 
acini when the agonist is withdrawn. 
2. MATERIALS AND METHODS 
Suspensions of dispersed acini were prepared from the pancreases 
of fasted male guinea pigs as described previously [9]. Disperse d acini 
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were cultured at 37°C for up to 48 h in a defined medium consisting 
of DME/FI2 supplemented with insulin, transferrin, selenium, 
bovine serum albumin, trypsin inhibitor, epidermal growth factor, 
ascorbate, Hepes (pH 7.4) and antibiotics [9]. In most experiments, 
acini were cultured first for 18-24 h with 0.1 mM carbachol to down 
regulate the muscarinic receptor population, rinsed, and recultured 
for an additional 24 h as above in the absence of drugs or in the 
presence of carbachol, tunicamycin, or cycloheximide, At the end of 
this second culture period, acini were collected and assayed for 
secretory responsiveness, [3H]mannose and [3H]leucine incorpo- 
ration, and binding of the muscarinic antagonist [~H]N-methylsco- 
polamine (NMS). 
For [3H]NMS binding, acini were resuspended in 5 ml of a Hepes- 
buffered Ringers solution (pH 7.4) containing 0.1%0 bovine serum 
albumin, 0.01%0 soybean trypsin inhibitor, and 0.5 nM [3H]NMS with 
or without 10 #M atropine. Acinar suspensions were incubated with 
the labelled antagonist for 60 min at 37°C, collected on Whatman 
GF/A glass fiber filters, rinsed, and counted as previously described 
[9]. Specific [3H]NMS binding was calculated as the difference in bin- 
ding in the absence and presence of atropine. Specific binding of the 
antagonist was related to DNA content, as determined by the 
diphenylamine procedure [10]. 
Effects of tunicamycin, carbachol, and cycloheximide on incor- 
poration of [3H]mannose and [3H]leucine into acinar macromolecules 
was determined during the second culture period. Acini were cultured 
in the presence of 2 #Ci/ml of [3H]mannose or 0.2 #Ci/ml of 
[3H]leucine in the absence of drugs, in the presence of 0.1 mM car- 
bachol or cycloheximide, or in the presence of 0.01-10 /zg/ml of 
tunicamycin. After 24 h of culture, acini were collected, rinsed, and 
resuspended and sonicated in distilled water. An equal volume of cold 
20% trichloroacetic acid was added and after 10 min at 40°C, 
precipitated protein was pelleted by centrifugation. After a second 
resuspension and rinse in cold 10% trichloroacetic a id, precipitated 
material was solubilized and counted. Incorporation of the two labell- 
ed precursors was normalized to DNA values. 
To assess possible effects of deglycosylation of acinar muscarinic 
receptors on cellular secretory responsiveness to carbachol, acini were 
incubated in the absence and presence of 3/~g/ml of tunicamycin dur- 
ing the second 24 h culture period. At the end of this period, both 
groups of acini were resuspended in Ringers solution as above con- 
taining a range of carbachol concentrations and incubated for 30 rain 
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at 37°C. Amylase released uring this period was determined using 
Procian yellow starch [11] and expressed as a percentage of total 
cellular amylase content. 
3. RESULTS 
3.1. Inhibition of recovery of [3H]N-methylscopo- 
lamine binding to acini 
We previously showed that the size of the muscarinic 
receptor population in cultured guinea pig pancreatic 
acini was decreased by 90070 after 18 h of exposure to 
0.1 mM carbachol [9]. Removal of the agonist from the 
culture nvironment allowed the receptor population to 
recover, so that by 24 h after carbachol was withdrawn 
the number of cell surface receptors present was in- 
creased several-fold. In the present work, we deter- 
mined the effects of cycloheximide and tunicamycin on 
this recovery. Inhibitory effects of cycloheximide on the 
increase in [3H]NMS binding seen after removal of car- 
bachol were first noticeable at 10 nM and appeared to 
be maximal at 0.1 mM (Fig. 1). The ICso for this effect 
was approximately 0.1 /LM. By contrast, tunicamycin 
caused only a small reduction in recovery of [3H]NMS 
binding sites (Fig. 2), even at quite high concentrations. 
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Fig. 2. Effect of tunicamycin on recovery of muscarinic receptors in 
pancreatic acini after carbachol-induced down regulation. Acini were 
cultured and [3H]NMS binding was determined as in Fig. 1. Results 
represent means _+ SE of 4 experiments. 
3.2. Effects of tunicamycin on [3H]mannose and 
[3 H]/eucine incorporation 
Since tunicamycin caused only a small inhibition of 
the recovery of [3H]NMS binding sites, we assessed its 
effects on both mannose and leucine incorporation i to 
acinar cell macromolecules (Fig. 3). Tunicamycin had a 
dramatic inhibitory effect on [~H]mannose incorpora- 
tion, reducing it by 85-90% at a concentration f 10 
#g/ml. By contrast, incorporation of [3H]leucine was 
only decreased by 20-25°7o at this concentration. These 
results clearly demonstrate the inhibitory specificity of 
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Fig. 1. Effect of cycloheximide onrecovery of muscarinic receptors in
pancreatic acini after carbachol-induced down regulation. Acini were 
cultured for 18 h with 0.1 mM carbachol, then for 24 h in the 
continued presence of the agonist carbachol (CCh), in the absence of 
drugs, and in the presence of various concentrations of 
cycloheximide. [3H]NMS binding to acini was determined atthe end 
of the second culture period. Results represent means + SE of 3 
experiments. 
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Fig. 3. Effects of tunicamycin, chcloheximide (ChX), and carbachol 
(CCh) on [3H]mannose (©) and [3H]leucine (el incorporation i to 
macromolecules in pancreatic acini. Acini were cultured as in Fig. 1 
for 18 h with 0.1 mM carbachol, then for 24 h with 0.1 mM carbachol, 
0.1 mM cycloheximide, or varying concentrations of tunicamycin. 
[3H]mannose or [3H]leucine was included in the culture medium 
during the second culture period. Results represent means + SE of 4 
experiments. 
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Fig. 4. Effect of tunicamycin treatment on secretory responsiveness of 
pancreatic acini. Acini were cultured as above with carbachol for 18 
h and then for 24 h either with no drugs (e) or with 3 /~g/ml of 
tunicamycin (©). At the end of this second culture period, the ability 
of both groups of acini to secrete amylase in response to a range of 
carbachol concentrations was assessed. Results represent means + SE 
of 5 experiments. 
tunicamycin and suggest hat the small decrease in 
[3H]NMS binding seen at high tunicamycin concentra- 
tions (Fig. 2) results from a general inhibitory effect on 
protein synthesis. As expected, 0.1 mM cycloheximide 
inhibited nearly all incorporation of both mannose and 
leucine, although carbachol had no effect on either. 
3.3. Effect of  tunicamycin on carbachol-induced 
amylase secretion 
A possible effect of tunicamycin on the functional 
properties of acinar muscarinic receptors also was prob- 
ed by comparing the ability of carbachol to stimulate 
digestive nzyme release from tunicamycin-treated an
control acini (Fig. 4). In both groups of acini, carbachol 
evoked abiphasic release of amylase, from a basal evel 
of 2-3% to 16-18% at a concentration f 0.3 mM. The 
ECso for stimulation of amylase release from both 
groups of acini was approximately 30#M. 
4. DISCUSSION 
This study demonstrates that in the pancreatic acinar 
cell, tunicamycin does not prevent the reappearance of 
muscarinic receptors at the cell surface during recovery 
of the receptor population from agonist-induced down 
regulation. Evidence that the increase in [3H]NMS 
binding sites does in fact represent integration of new 
receptor protein into the acinar cell plasma membrane 
is two-fold. First, [~H]NMS is a quaternary muscarinic 
antagonist of low lipid solubility and there is now con- 
siderable vidence that it labels only cell surface recep- 
tors [12]. A second line of evidence is illustrated in Fig. 
4. When guinea pig pancreatic acini are cultured for 
18-24 h in the presence of carbachol, their secretory 
responsiveness i  virtually nil [9]. Yet after 24 h of 
subsequent culture in the absence of the agonist, they 
are again able to respond in a vigorous fashion, whether 
or not tunicamycin s included in the culture medium. 
The fact that these newly synthesized receptors can 
mediate carbachol stimulation of amylase release in- 
dicates that they are located in the plasma membrane 
and are in functional association with the complex of 
primary effectors that generates appropriate in- 
tracellular messengers. These results also suggest that 
exposure of acini to tunicamycin does not alter the 
agonist binding properties of the pancreatic muscarinic 
receptor, as is also the case for the reticulocyte beta 
adrenergic receptor [13]. 
Although it has been demonstrated [8] that disrup- 
tion of normal glycosylation pathways in a mouse 
neuroblastoma cell line with tunicamycin also decreased 
cell surface expression of muscarinic receptors, this 
does not appear to be the case for pancreatic acinar 
cells. These observations may reflect cell-specific dif- 
ferences in processing pathways or differences 
characteristic of the particular muscarinic receptor sub- 
types expressed. The cell surface expression of some 
other integral plasma membrane proteins, including 
receptors for insulin [14], have been shown to be sen- 
sitive to tunicamycin, although Zamofing and col- 
leagues [15] recently showed that deglycosylation f the 
nascent beta subunit of Na÷,K÷-ATPase in toad 
urinary bladder cells with tunicamycin does not prevent 
its insertion into the plasma membrane. Results 
presented in the present study indicate that glycosyla- 
tion of the M3 muscarinic receptor subtype in the pan- 
creatic acinar cell is not a prerequisite for its proper in- 
sertion in the plasma membrane and that glycosyl 
residues on the receptor do not play an important role 
in its ability to interact with agonists. 
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